Suppliers and packagers for victoza

victoza

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341	NDA	Novo Nordisk	0169-4060-12	2 SYRINGE, PLASTIC in 1 CARTON (0169-4060-12) / 3 mL in 1 SYRINGE, PLASTIC	2010-01-25
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341	NDA	Novo Nordisk	0169-4060-13	3 SYRINGE, PLASTIC in 1 CARTON (0169-4060-13) / 3 mL in 1 SYRINGE, PLASTIC	2010-01-25
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341	NDA	Novo Nordisk	0169-4060-90	1 SYRINGE, PLASTIC in 1 CARTON (0169-4060-90) / 3 mL in 1 SYRINGE, PLASTIC	2010-01-25
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341	NDA	Novo Nordisk	0169-4060-99	1 SYRINGE, PLASTIC in 1 CARTON (0169-4060-99) / 3 mL in 1 SYRINGE, PLASTIC	2010-01-25

Victoza (semaglutide) Active Pharmaceutical Ingredient and Excipient Suppliers

Last updated: February 19, 2026

This analysis identifies key suppliers of semaglutide, the active pharmaceutical ingredient (API) for Victoza, and critical excipients used in its formulation. It details manufacturing capabilities, regulatory compliance, and supply chain considerations relevant to pharmaceutical R&D and investment professionals.

Who Manufactures Semaglutide API?

Novo Nordisk holds the primary manufacturing responsibility for semaglutide API. However, the complexity of peptide synthesis and the global pharmaceutical supply chain necessitate a multi-faceted approach involving contract manufacturing organizations (CMOs). Identifying specific CMOs involved in semaglutide production is challenging due to proprietary agreements and confidentiality clauses common in pharmaceutical manufacturing. Publicly available information and industry analysis suggest that large, experienced peptide manufacturers are likely involved.

• Novo Nordisk: As the innovator and originator of semaglutide, Novo Nordisk maintains significant in-house API manufacturing capacity at its facilities. This provides a core supply and control over critical aspects of production.
• Contract Manufacturing Organizations (CMOs): Specialized CMOs with expertise in complex peptide synthesis are essential for scaling production and mitigating supply chain risks. These entities typically operate under strict Good Manufacturing Practice (GMP) regulations and are subject to regulatory inspections by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • While specific CMO names for semaglutide are not publicly disclosed by Novo Nordisk, companies known for large-scale peptide API production and with established relationships with major pharmaceutical firms are candidates. These include organizations with proven track records in:
    • Solid-phase peptide synthesis (SPPS) or liquid-phase peptide synthesis (LPPS) at commercial scale.
    • High-purity peptide purification techniques.
    • Handling complex regulatory documentation and validation processes.

What Are the Key Excipients for Victoza Formulation?

Victoza is an injectable solution. Its formulation relies on a range of excipients to ensure stability, solubility, bioavailability, and proper delivery. The primary excipients include:

• Disodium Phosphate Dihydrate: A buffering agent used to maintain the pH of the solution.
  • Role: Stabilizes the peptide and ensures optimal solubility.
  • CAS Number: 10028-24-7
  • Typical Purity: Pharmaceutical grade, meeting USP/NF or Ph. Eur. monographs.
  • Suppliers: Numerous global chemical manufacturers supply pharmaceutical-grade phosphates. Examples of large suppliers include Thermo Fisher Scientific, Sigma-Aldrich (Merck KGaA), and various specialized industrial chemical producers.
• Monosodium Phosphate Monohydrate: Another buffering agent that works in conjunction with disodium phosphate to control pH.
  • Role: Contributes to pH adjustment and stability.
  • CAS Number: 10049-21-5
  • Typical Purity: Pharmaceutical grade, meeting USP/NF or Ph. Eur. monographs.
  • Suppliers: Similar to disodium phosphate, major chemical suppliers and distributors provide this excipient.
• Sodium Chloride: Used as a tonicity-adjusting agent.
  • Role: Makes the solution isotonic with bodily fluids, reducing injection site discomfort.
  • CAS Number: 7647-14-5
  • Typical Purity: Pharmaceutical grade, meeting USP/NF or Ph. Eur. monographs.
  • Suppliers: Widely manufactured and supplied by global chemical companies, including AkzoNobel, Cargill, and numerous regional manufacturers.
• Phenol: Acts as a preservative.
  • Role: Prevents microbial growth in the multi-dose vial formulation.
  • CAS Number: 108-95-2
  • Typical Purity: Pharmaceutical grade, meeting USP/NF or Ph. Eur. monographs.
  • Suppliers: Companies specializing in pharmaceutical excipients and fine chemicals. Examples include Dow Chemical Company, BASF, and VWR International.
• Water for Injection (WFI): The primary solvent.
  • Role: Dissolves the API and excipients to create the final injectable solution.
  • Specifications: Must meet stringent USP/NF or Ph. Eur. purity standards, free from pyrogens and microbial contamination.
  • Production: Typically produced on-site at the drug manufacturing facility using methods such as distillation or reverse osmosis, or sourced from highly purified water providers with GMP compliance.

Excipient Supplier Considerations

• Regulatory Compliance: All excipient suppliers must adhere to GMP standards. This includes robust quality management systems, detailed documentation (e.g., Certificates of Analysis, Drug Master Files or equivalent), and audit readiness.
• Supply Chain Security: Diversification of suppliers for critical excipients is a standard risk mitigation strategy for pharmaceutical manufacturers.
• Geographic Location: Proximity and logistical capabilities of suppliers can impact lead times and transportation costs.
• Scalability: Suppliers must demonstrate the capacity to meet the large-volume demands of a blockbuster drug like Victoza.

What Are the Regulatory Requirements for API and Excipient Manufacturing?

The manufacturing of both semaglutide API and pharmaceutical excipients for use in Victoza is governed by stringent regulatory frameworks to ensure product safety, efficacy, and quality.

• Good Manufacturing Practice (GMP):
  • API: ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is the primary guideline. This covers quality management, personnel, buildings and facilities, process equipment, documentation and records, materials management, production and in-process controls, packaging and labeling, storage and distribution, laboratory controls, validation, and change control.
  • Excipients: While not always as rigidly defined as API GMP, excipient manufacturers are increasingly expected to comply with GMP principles relevant to their product's intended use. For critical excipients used in injectables, compliance with USP General Chapter <1078> Good Manufacturing Practices for Bulk Pharmaceutical Excipients or equivalent international standards is common.
• Regulatory Filings:
  • Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory agencies (e.g., FDA in the U.S.). These confidential documents contain detailed information about the manufacturing process, quality controls, and stability of the API. The drug product applicant (Novo Nordisk) references the DMF in its marketing authorization application.
  • Certificates of Suitability (CEPs): In Europe, CEPs issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrate that an API complies with the European Pharmacopoeia monograph.
  • Excipient Specifications: Excipient suppliers provide Certificates of Analysis (CoAs) with each batch, confirming it meets agreed-upon specifications. For critical excipients, more extensive documentation and quality agreements are established between the drug manufacturer and the supplier.
• Agency Inspections: Manufacturing sites for both API and excipients are subject to periodic inspections by regulatory authorities (e.g., FDA, EMA, PMDA) to verify compliance with GMP.
• Quality Agreements: Formal quality agreements are established between Novo Nordisk and its API and critical excipient suppliers. These agreements define responsibilities for quality control, change management, deviation investigations, and regulatory reporting.

How Do Supply Chain Dynamics Affect Victoza Production?

The production of Victoza, like other complex biopharmaceuticals, is sensitive to global supply chain dynamics.

• API Supply Chain:
  • Peptide Synthesis Complexity: Semaglutide is a peptide, and its synthesis is a complex, multi-step chemical process. Scaling up peptide synthesis requires specialized equipment, highly skilled personnel, and rigorous quality control at each stage.
  • Raw Material Sourcing: The precursor amino acids, reagents, and solvents used in peptide synthesis are critical raw materials. Disruptions in the supply of these upstream materials can impact API production.
  • CMO Dependency: Reliance on CMOs for a portion of the API supply introduces potential risks related to CMO capacity, regulatory compliance, and geopolitical stability in their operating regions.
• Excipient Supply Chain:
  • Quality and Consistency: Ensuring a consistent supply of high-purity, pharmaceutical-grade excipients is paramount. Any deviation in excipient quality can lead to batch failures or product recalls.
  • Global Sourcing: Excipients are sourced globally. Trade policies, shipping disruptions, and natural disasters can affect availability and lead times.
  • Limited Number of Specialized Suppliers: For certain highly purified or specialized excipients, the supplier base may be more concentrated, increasing vulnerability to single-source disruptions.
• Geopolitical and Economic Factors:
  • Trade Tariffs and Regulations: Changes in international trade policies can impact the cost and availability of raw materials and finished APIs.
  • Pandemics and Health Crises: Events like the COVID-19 pandemic demonstrated the fragility of global supply chains, leading to shortages of raw materials, increased shipping costs, and production slowdowns.
  • Environmental Regulations: Increasingly stringent environmental regulations in manufacturing regions can impact production costs and capacities.

What Are the Key Risks and Mitigation Strategies for Victoza Suppliers?

Risk Category	Specific Risk	Mitigation Strategy
API Supply	Single-source dependency: Over-reliance on a single CMO or internal manufacturing site for semaglutide API.	Dual Sourcing Strategy: Qualify and establish manufacturing agreements with at least two distinct, reputable CMOs or invest in redundant internal manufacturing capacity for critical API steps. Inventory Management: Maintain strategic buffer stocks of API and critical raw materials. Supplier Audits and Monitoring: Conduct regular, rigorous audits of API suppliers and their upstream raw material providers.
	Technical Challenges in Peptide Synthesis: Difficulties in scaling up complex peptide synthesis or maintaining consistent purity and yield.	Process Optimization and Robustness: Invest in continuous process development and validation to ensure robustness and minimize batch-to-batch variability. Strong Technical Partnerships: Foster close collaborations with CMOs and technology providers to leverage specialized expertise.
Excipient Supply	Quality Deviations: Sub-standard quality excipients leading to batch failures or product rejection.	Stringent Supplier Qualification and Testing: Implement a rigorous supplier qualification program including site audits, extensive pre-qualification testing, and lifecycle management. Dual Sourcing and Buffer Stocks: Secure multiple qualified suppliers for critical excipients and maintain adequate inventory. Quality Agreements: Establish comprehensive quality agreements with all excipient suppliers.
	Supply Disruptions: Interruption of excipient supply due to natural disasters, geopolitical events, or the closure of a key supplier.	Geographic Diversification: Source critical excipients from suppliers in different geographic regions to reduce exposure to localized disruptions. Contingency Planning: Develop contingency plans for alternative suppliers and transportation routes.
Regulatory Compliance	GMP Violations: Non-compliance with GMP regulations by API or excipient manufacturers leading to regulatory actions, production halts, or product recalls.	Proactive Compliance Culture: Foster a strong culture of compliance within supplier organizations. Continuous Training and Education: Ensure personnel are adequately trained on GMP requirements. Internal Audits and Self-Inspections: Conduct frequent internal audits and self-inspections to identify and rectify potential compliance issues before regulatory inspections.
	Changes in Regulatory Landscape: New or revised regulations impacting manufacturing processes or product specifications.	Regulatory Intelligence: Establish robust systems for monitoring global regulatory changes. Proactive Engagement: Engage with regulatory bodies and industry associations to stay informed and contribute to policy development. Flexible Manufacturing Processes: Design manufacturing processes with inherent flexibility to adapt to evolving regulatory requirements.
Logistics & Distribution	Shipping Delays and Cost Volatility: Increased lead times and transportation expenses for raw materials and finished goods.	Strategic Logistics Partnerships: Collaborate with experienced and reliable logistics providers. Optimize Shipping Routes: Analyze and optimize shipping routes for efficiency and cost-effectiveness. Forward Planning: Implement advanced planning and forecasting for material needs and shipment schedules.
Intellectual Property	Patent Expirations and Generic Competition: Risk of market entry by generic manufacturers upon patent expiry, impacting market share and pricing.	Life Cycle Management: Develop and implement strategies for post-patent protection, such as developing next-generation products or exploring new indications. Robust Patent Portfolio: Maintain a strong and defensible patent portfolio.

Key Takeaways

• Novo Nordisk primarily manufactures semaglutide API, with likely reliance on specialized peptide synthesis CMOs for scaled production, though specific partners are undisclosed.
• Key excipients include disodium phosphate dihydrate, monosodium phosphate monohydrate, sodium chloride, phenol, and water for injection, sourced from global pharmaceutical-grade chemical manufacturers.
• All API and critical excipient manufacturing must comply with stringent GMP regulations, requiring robust quality management systems and detailed regulatory documentation.
• Supply chain risks are significant, ranging from API synthesis complexity and raw material sourcing to geopolitical instability and excipient quality consistency.
• Mitigation strategies for suppliers involve dual sourcing, strategic inventory management, rigorous supplier qualification, proactive regulatory compliance, and resilient logistics planning.

FAQs

1. What are the primary challenges in sourcing semaglutide API for generic manufacturing? Generic manufacturers face significant challenges in sourcing semaglutide API due to the complexity of peptide synthesis, Novo Nordisk's patent protection, and the requirement for extensive validation and regulatory approval for any new API source. Identifying and qualifying CMOs capable of producing high-purity semaglutide at scale under GMP conditions is a major hurdle.

2. How does Novo Nordisk ensure the quality and reliability of its excipient suppliers? Novo Nordisk employs a rigorous supplier qualification process that includes comprehensive audits of manufacturing facilities for GMP compliance, thorough review of quality systems and documentation, and ongoing performance monitoring. They establish detailed quality agreements to define responsibilities and ensure consistent adherence to specifications.

3. What is the typical lead time for procuring pharmaceutical-grade excipients for large-volume drug production? Lead times for pharmaceutical-grade excipients can vary widely but typically range from 4 to 12 weeks for established products and suppliers. For highly specialized or custom-manufactured excipients, lead times can extend to several months. This necessitates robust inventory management and long-term forecasting by drug manufacturers.

4. Are there alternative preservatives to phenol that could be used in semaglutide formulations? While phenol is a common and effective preservative in many injectable formulations, alternative preservatives such as benzyl alcohol, parabens, or m-cresol are used in other pharmaceutical products. However, any change in preservative for an established drug like Victoza would require extensive reformulation, stability testing, and regulatory re-approval, which is a significant undertaking.

5. What are the implications of geopolitical instability on the supply of Victoza's raw materials and API? Geopolitical instability can disrupt the supply chain at multiple levels. It can affect the availability and cost of precursor chemicals and reagents used in API synthesis, impact logistics and transportation routes for both raw materials and finished API, and potentially lead to trade restrictions or sanctions that hinder cross-border commerce. This necessitates diversification of sourcing and robust risk management plans.

Citations

[1] United States Food and Drug Administration. (n.d.). Guidance for Industry - ANDAs: API’s (Active Pharmaceutical Ingredients). U.S. Food and Drug Administration. Retrieved from www.fda.gov (Specific guidance document URLs change; general search on FDA.gov for API manufacturing is recommended). [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). European Medicines Agency. Retrieved from www.ema.europa.eu (General information on GMP). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Harmonised Tripartite Guideline - Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. ICH. [4] United States Pharmacopeia. (n.d.). USP General Chapter <1078> Good Manufacturing Practices for Bulk Pharmaceutical Excipients. U.S. Pharmacopeia. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). EDQM. Retrieved from www.edqm.eu.